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Summary
Background: The gastrointestinal microbiota has an important role in mucosal im-
mune homoeostasis and may contribute to maintaining mucosal healing in Crohn's 
disease (CD).
Aim: To identify changes in the microbiota, metabolome and protease activity associ-
ated with mucosal healing in established paediatric CD.
Methods: Twenty-five participants aged 3-18 years with CD, disease duration of over 
6 months, and maintenance treatment with biological therapy were recruited. They 
were divided into a low calprotectin group (faecal calprotectin <100 μg/g, “mucosal 
healing,” n = 11), and a high calprotectin group (faecal calprotectin >100 μg/g, “mu-
cosal inflammation,” n = 11). 16S gene-based metataxonomics, 1H-NMR spectros-
copy-based metabolic profiling and protease activity assays were performed on stool 
samples.
Results: Relative abundance of Dialister species was six times greater in the low cal-
protectin group (q = 0.00999). Alpha and beta diversity, total protease activity and 
inferred metagenomic profiles did not differ between groups. Pentanoate (valerate) 
and lysine were principal discriminators in a machine-learning model which differen-
tiated high and low calprotectin samples using NMR spectra (R2 0.87, Q2 0.41). Mean 
relative concentration of pentanoate was 1.35-times greater in the low calprotec-
tin group (95% CI 1.03-1.68, P = 0.036) and was positively correlated with Dialister. 
Mean relative concentration of lysine was 1.54-times greater in the high calprotectin 
group (95% CI 1.05-2.03, P = 0.028).
Conclusions: This multiomic study identified an increase in Dialister species and pen-
tanoate, and a decrease in lysine, in patients with “mucosal healing.” It supports fur-
ther investigation of these as potential novel therapeutic targets in CD.
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1  | INTRODUC TION
Crohn's disease (CD) is a chronic inflammatory disease caused by an 
inappropriate immunological response to the gastrointestinal micro-
biota in genetically susceptible individuals. Transmural inflammation 
throughout the gastrointestinal tract causes pain, bleeding, weight 
loss and diarrhoea; ultimately resulting in long-term complications 
such as stricture and fistula formation. Children with CD typically 
have more aggressive disease and worse long-term outcomes than 
those with adult onset disease.1
Treatment of paediatric CD aims to control symptoms and to 
suppress mucosal inflammation. Adequate suppression of inflamma-
tion results in mucosal healing, which is associated with improved 
long-term outcomes.1,2 Low faecal calprotectin levels are a well val-
idated non-invasive marker of mucosal healing in CD.3-6 The faecal 
calprotectin threshold which defines mucosal healing has not been 
universally agreed, studies support values in the range of 100-
300 μg/g,3-8 with a value of 100 μg/g used most frequently.9 In pae-
diatric CD Weinstein-Nakar et al7 found faecal calprotectin levels 
under 100 μg/g were predictive of mucosal and transmural healing.
Inducing and maintaining mucosal healing is a major challenge. 
Over 25% of all paediatric CD patients are now escalated to an-
ti-TNF and other biological therapies,10 but approximately one in 
three patients will not have a sustained response to maximal medical 
therapy.11,12
The gastrointestinal microbiome has an important role in mu-
cosal immune homoeostasis and evidence from epidemiological 
studies and mouse models suggest it is involved in the pathogenesis 
of CD.13,14 There are several mechanisms by which the microbiota 
could promote mucosal healing or exacerbate mucosal inflammation 
in established disease.15
Changes to the microbiota's metabolic capacity alter the muco-
sal concentration of active metabolites. The short-chain fatty acids 
(SCFAs) acetate, propionate, butyrate and pentanoate (also known 
as valerate) are produced by bacterial metabolism of dietary fibre 
and amino acids,16 and are present in reduced concentration in CD.17 
SCFAs act as a primary energy source for enterocytes, promote tight 
junction formation and induce anti-microbial protein formation.18 
Butyrate18,19 and pentanoate20 induce anti-inflammatory cytokine 
production and modify immune cell differentiation via their activa-
tion of free fatty acid receptors and inhibition of histone deacetyl-
ase. Immunomodulatory properties of other metabolites, including 
bile acid metabolites21 and amino acids,22 have also been described.
Protease activity in the gastrointestinal lumen is influenced by 
microbial metabolism. Bacteria produce proteases, and also degrade 
or inhibit host pancreatic and inflammatory proteases. Protease ac-
tivity is increased in IBD,23 and can influence disease activity by in-
ducing invasive behaviour in commensal bacteria24 or by degrading 
tight junction proteins.25 Pro-inflammatory signalling cascades are 
initiated by protease activated receptors on enterocytes, fibroblasts 
and mucosal immune cells.24,25
Previous studies have characterised the microbiome of paediat-
ric CD patients relative to controls and found reduced diversity, high 
instability and altered relative abundance of multiple bacterial gen-
era.26,27 Increased mucosal inflammation has been associated with a 
greater reduction in alpha diversity, as well as reduced abundance of 
SCFA producers such as Faecalibacterium prausnitzii26 and Roseburia 
hominis.28,29 Conversely, inducing remission with anti-TNF induction 
makes the microbiota more similar to that of healthy children.30 It is 
not known whether inflammation associated microbial differences 
persist in established disease, or whether they contribute to ongoing 
mucosal healing or inflammation.
This study aims to identify changes in the microbiota which are 
associated with mucosal healing in established paediatric CD and to 
investigate the functional implications of these changes using inferred 
metagenomics, 1H-NMR metabolomics and protease activity assays.
2  | MATERIAL S AND METHODS
2.1 | Study design and participant recruitment
Participants were recruited to the “Metabolic and Microbiome 
Profiling in Paediatric IBD” study, a multi-centre clinical cohort study 
in North-West London. The parents or carers of all study participants 
provided informed consent to join the study, and the study partici-
pants signed age appropriate assent forms. The study design and 
objectives were approved by London Bloomsbury research ethics 
committee (REC reference 17/LO/2049). All patients included in this 
analysis had a confirmed diagnosis of paediatric CD and a disease 
duration of greater than 6 months. All were receiving maintenance 
biological therapy, which was defined as regular treatment with in-
fliximab, adalimumab or vedolizumab beyond the induction phase.
Clinical data were obtained from review of electronic medical re-
cords and from a questionnaire completed at induction to the study. 
C-reactive protein, erythrocyte sedimentation rate, haemoglobin 
concentration and stool calprotectin concentration were tested as 
part of routine clinical care.
All participants provided a sample of a whole stool for microbi-
ome, metabolome and protease activity analysis. Stool samples were 
collected using a “fecotainer” system (Excretas Medical). The sample 
was immediately refrigerated to 4°C and was homogenised, divided 
and frozen at minus 80°C within 4 hours of production. Sample 
order was randomised prior to further analysis.
The low calprotectin group was defined by a calprotectin con-
centration of less than 100 μg/g, which was used as a surrogate 
for mucosal healing, and the high calprotectin group by a concen-
tration of 100 μg/g or over. Calprotectin value was used to assign 
groups if it was measured in the same stool sample as that used 
for the study analyses, or if two stable calprotectin values were 
recorded within the 2 months before and after collection of the 
sample used for study analyses and there had been no change in 
clinical disease activity or treatment in this period. Samples with-
out a corresponding calprotectin measurement meeting these 
requirements were not included in the high and low calprotec-
tin groups, but were included for analyses which did not require 
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calprotectin value, that is, correlation analyses between microbi-
ome and metabolome.
Baseline characteristics were compared between groups using 
Welch t test for continuous variables, and the chi-squared test for 
categorical variables (where test validity requirements were met).
2.2 | Metataxonomic analysis
Metataxonomic analysis (16S rRNA gene sequencing) was per-
formed on DNA extracted from thawed stool samples. The 
V1-2 region of the 16S rRNA gene was used for taxonomic 
discrimination.31-33
2.2.1 | DNA extraction and sequencing
DNA was extracted using the Powerlyzer PowerSoil DNA isola-
tion kit (Qiagen) according to the manufacturers protocol except 
samples were lysed by bead beating for 3 minutes at speed 8 using 
a Bullet Blender Storm instrument (Thistle Scientific). Sample li-
braries were prepared using a protocol adapted from Illumina's 
16S Metagenomic Sequencing Library Preparation Protocol,34 
which has been previously described.35 The V1-V2 region of 16S 
rRNA gene were amplified using the primers listed in Table S1. 
SequalPrep Normalization Plate Kit (Thermo Fischer Scientific) 
was used to normalise index PCR reactions, and NEBNext Library 
Quant Kit for Illumina (New England Biolabs) was used to quantify 
sample libraries. Sequencing was performed on an Illumina MiSeq 
platform (Illumina Inc) using paired-end 300 bp chemistry and the 
MiSeq Reagent Kit v3 (Illumina).
2.3 | Data analysis
16S rRNA gene sequence data were analysed using the DADA2 
pipeline (version 1.12)36 in R (R Foundation). Outlier analysis (ROUT, 
Q = 1) of the number of sequences from each sample was performed 
using GraphPad Prism (GraphPad Software). The vegan package in 
R was used to calculate Shannon index, species richness and Pielou 
evenness for all samples. A neighbour-joining phylogenetic tree was 
constructed using the R packages DECIPHER and phangorn, and 
the phyloseq package37 was used to calculate weighted UniFrac dis-
tances. Weighted UniFrac distance was compared between groups 
using non-metric multidimensional scaling (NMDS) and permuta-
tional analysis of variance (PERMANOVA), performed using the R 
packages vegan and ggplot 2.
The amplicon sequence variant (ASV) table produced by 
DADA2 was formatted by grouping rare variants followed by sub-
sampling data to the level of the sample with the lowest summed 
read count which was 7114 reads. No samples were identified as 
an outlier for summed read count using GraphPad Prism (ROUT, 
Q = 1). STAMP38 was used to analyse difference in relative 
abundance between high and low calprotectin groups at all tax-
onomic levels from genus to phylum. Two group comparison was 
performed in STAMP using two-sided White's non-parametric 
t test with Benjamini-Hochberg correction for multiple testing 
(q < 0.05 was considered significant). Results were filtered to se-
lect only those where the difference in the mean proportion of 
sequences was greater than 1%.
2.3.1 | Inferred metagenomic analysis
Inferred metagenomic analysis was performed using Piphillin, which 
is the best performing tool for predicting metagenome composi-
tion in clinical biosamples.39 Three outputs were analysed: KEGG 
pathways, KEGG orthologs and BioCyc features. All were formatted 
by subsampling to the level of the sample with the lowest summed 
counts (1.51 × 106, 7.98 × 106, and 2.84 × 106 respectively). Two-
group comparison was performed in STAMP using the same pa-
rameters as above. An effect size filter of 0.1% difference between 
pathway, ortholog or feature expression was used.
2.4 | Protease activity assay
A mixture of one-part thawed stool sample and two parts phos-
phate-buffered saline (PBS) were vortexed with microbeads at 2850 
revolutions per minute for 5 minutes using the Vortex Genie 2 with 
microcentrifuge tube adaptor (Scientific industries Inc). The homog-
enised mixture was centrifuged at 20 000 g for 20 minutes. Faecal 
water was prepared by passing 500 μl supernatant through 5.0 μm 
centrifugal filter (12 000 g, 3 minute spin). PBS was added in appro-
priate volume to prepare 10- and 100-fold dilutions of faecal water.
Protein concentration of faecal water dilutions was measured and 
compared against bovine serum albumin standards using the colori-
metric Pierce BCA Protein assay following the manufacturer's pro-
tocol (Thermo Fischer Scientific). Protein concentration in the faecal 
water was normalised to 1mg/ml by addition of PBS. Dilutions of 
the 1mg/ml faecal water and trypsin standard were prepared. These 
were added to an FTC-Casein substrate and working reagent from 
the Pierce Fluorescent Protease Assay kit (Thermo Fischer Scientific) 
as per the manufacturers protocol. Proteolysis of the substrate was 
measured by fluorescent resonance energy transfer using a FLUOstar 
OPTIMA (BMG LABTECH). Total protease activity of faecal water was 
expressed relative to the activity of trypsin standards in ng/ml concen-
tration (relative units). All assays performed in triplicate.
The activity of protease subtypes was assessed by performing 
the above protease activity assay, but with the co-incubation of a 
protease inhibitor (Roche Diagnostics) with the faecal solution for 
5 minutes, prior to addition of the working reagent. Optimal inhibitor 
concentrations were determined in preliminary work and inhibitor 
specificity confirmed by searching the MEROPS database.40 The 
following inhibitors were used: Antipain-dihydrochloride (50 μg/ml), 
Leupeptin (5 μg/ml), or a combination of antipain-dihydrochloride 
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(50 μg/ml), aprotinin (2 μg/ml) and Pefabloc (1 mg/ml). Assays were 
performed in duplicate. Degree of inhibition was calculated as ratio 
of protease activity in inhibited and uninhibited wells. Protease sub-
type activity (Δ protease activity) was calculated as total protease 
activity multiplied by degree of inhibition. Outliers for protease and 
protease subtype activity were identified using GraphPad Prism 
(ROUT, Q = 1) and excluded from further analysis. Welch's t test was 
performed to compare total protease and protease subtype activity 
between groups. Bonferroni correction was used to correct p values 
from protease subtype activity analysis.
2.5 | Metabolome analysis
2.5.1 | Sample preparation for NMR analysis
Faecal water extraction was carried out by homogenising each sam-
ple with water (UHPLC grade, Fisher Chemical) at a ratio of 1:2 (mg of 
wet weight of faecal sample: μL of water). The mixture was vortexed 
for 5 minutes and centrifuged at 18 000 g and 4°C for 20 minutes, 
540 μL of the supernatant were mixed with 60 μL of 1.5 M KH2PO4 
buffer (pH 7.4, 100% of deuterium oxide (D2O), 2 mM sodium azide 
and 1% of TSP (3-trimethylsilyl-[2,2,3,3,-2H4]-propionic acid sodium 
salt). The mixture was centrifuged at 18 000 g at 4°C for 1 min. An 
aliquot of 580 μL of the supernatant was transferred into a 5 mm 
outer diameter NMR tube as described previously.41
2.5.2 | 1H-NMR spectroscopy
Water-suppressed 1H NMR spectroscopy was performed at 300 K on 
a Bruker 600 MHz Avance III HD spectrometer (Bruker Biospin). The 
1D 1H NMR spectra were acquired using standard one-dimensional 
pulse sequence, with saturation of the water resonance (noesygp-
pr1d pulse program) during both the relaxation delay (RD = 4s) and 
mixing time (tm = 10 ms). The two magnetic field z-gradients imple-
mented by this pulse sequence are applied for 1 ms The receiver 
gain was set to 90.5 and acquisition time (ACQ) to 2.73s for all ex-
periments. Each 1-dimensional (1D) 1H-NMR spectrum was acquired 
using 4 dummy scans, 32 scans, 64 K data points and with a spectral 
window of 20 ppm. Prior to Fourier Transformation, each free induc-
tion decay was multiplied by an exponential function corresponding 
to a line broadening of 0.3 Hz.
2D 1H − 1H J-resolved experiment was also acquired for each 
sample to detect the J-couplings in the second dimension using the 
pulse program with suppression of the water resonance during the 
relaxation delay (jresgpprqf). The acquisition parameters used for this 
experiment were as follows: 16 dummy scans and 2 scans, 8K points 
with spectral window of 16.7 ppm for f2 and 40 increments with a 
spectral window of 78 Hz for f1, incremented delay of 3μs, RD of 2 s 
and ACQ of 0.41 s. The receiver gain was set to 90.5. A sine-bell apod-
ization function was applied on both dimensions, followed by Fourier 
transformation, tilting by 45°, and symmetrisation along f1.42
2D-NMR experiments including 1H−1H Total Correlation 
Spectroscopy (TOCSY) and 1H−13C Heteronuclear Single Quantum 
Coherence (HSQC) were acquired for a representative sample for 
identification purposes.
2.5.3 | Spectral data analysis
1D 1H-NMR spectra were phased, baseline corrected and calibrated 
to TSP peak at δ1H 0 ppm prior to being digitised over the range δ1H 
−0.5 to 11 ppm, and imported into MATLAB (2014a, MathWorks). 
Spectral regions containing residual water (δ1H 4.69-4.93), TSP (δ1H 
−0.50 to 0.62) and noise (δ1H 9.35-11.00) were removed prior to 
probabilistic quotient normalisation.43
The data set was auto-scaled and modelled using Partial Least 
Squares Discriminant Analysis (PLS-DA) in a Monte Carlo Cross-
Validation (MCCV) framework using Storey-Tibshirani method of 
correction for multiple testing.44 Variables with q < 0.05 were con-
sidered to be significant. Goodness of fit (R2Y) was calculated using 
the training data, and the goodness of prediction (Q2Y) from test 
data. For discriminant analysis, calprotectin was used as dummy vari-
able (Y = 0 and 1 for high and low calprotectin respectively).
2.5.4 | Identification of metabolites
The structural identification of significant metabolites was achieved 
by 2D-NMR experiments and Subset Optimization by Reference 
Matching (STORM) on 1D 1H-NMR data set.45 Internal and exter-
nal databases such as the Human Metabolome Data Base (HMDB; 
http://hmdb.ca/)46 and/or the Biological Magnetic Resonance Data 
Bank (BMRB; http://www.bmrb.wisc.edu) were used for confirma-
tion of assignments.
Relative concentrations were calculated for metabolites that had 
significant correlation with Dialister and those that were observed as 
discriminators on the MCCV-PLS-DA model. This was performed by 
taking the integral from normalised spectra of a representative reso-
nance peak of pentanoate at 1.30 (δ1H range from 1.27 to 1.33), lysine 
at 1.73 (δ1H range from 1.69 to 1.76), beta-alanine at 2.56 (δ1H range 
from 2.55 to 2.58) and phenylalanine at 7.43 ppm (δ1H range from 7.41 
to 7.45). The integral of a peak represents a relative concentration of 
its corresponding metabolite. Mean metabolite relative concentration 
was compared between high and low calprotectin groups.
2.5.5 | Metataxonomic-Metabolome 
correlation analysis
Full resolution NMR spectral features were correlated with rela-
tive abundance data at five taxonomic levels (genera – phyla) using 
Spearman's rank correlation coefficient with Storey-Tibshirani 
method for multiple testing correction. A threshold of │ρ│≥0.5 with 
q < 0.05 was used to indicate a significant correlation.
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2.5.6 | Metabolic network analysis
Metabolites that had significant correlation with Dialister and those 
that were observed as discriminators on the MCCV-PLS-DA model 
were used to construct a condensed multicompartmental metabolic 
reaction network using MetaboNetworks v.2.3.47 This software is an 
agnostic bioinformatic tool that can reconstruct the pathway rela-
tionship observed in a real system, which is visualised as classical 
representation (KEGG). It calculates the shortest paths (number of 
reactions) between metabolites, including only the reactions that 
can occur in humans considered as a supra-organism. A custom 
metabolic reaction network was constructed using enzymes linked 
to Homo sapiens genes and enzymes linked to bacteria present in 
the gastrointestinal tract. Species from genera with >1.5% relative 
abundance in either the high or low calprotectin group (Figure S2), 
and that had genomic data available on the KEGG organism database 
were selected for inclusion in the analysis.
2.5.7 | Metabolic potential of Dialister species
In order to identify the most appropriate reference genome to assess 
the metabolic potential of Dialister, species level analysis was per-
formed for the Dialister genus. The 334 base pair ASVs from Dialister 
(Table S2) were matched against 16S sequences in the rRNA/ITS da-
tabase (National Centre for Biotechnology Information (NCBI), up-
dated 4 July 2020) using the megaBLAST48 nucleotide search tool. 
Species identity was assigned if there was 98.7% sequence match to 
a reference strain.49 This confidence threshold has high accuracy for 
species identification when using the V1-2 region of the 16S rRNA 
gene.33
The NCBI reference sequence linked to the representative strain 
was used to generate a metabolic pathway map using MetaCyc 
(https://metac yc.org).50
2.6 | Sensitivity analyses
The metataxonomic, protease activity and metabolome data 
analysis were repeated for two sensitivity analyses. The first was 
performed due to the uncertainty surrounding the appropriate 
threshold of faecal calprotectin which indicates mucosal healing. 
Values of 100-300 μg/g have been suggested as appropriate thresh-
olds. Participants with faecal calprotectin concentrations between 
100 and 300 μg/g were therefore excluded, leaving only those with 
faecal calprotectin levels which are widely accepted to predict mu-
cosal healing or mucosal inflammation.
The second sensitivity analysis excluded participants who were 
receiving vedolizumab. Vedolizumab is an α4β7 integrin antagonist, 
it has a different mechanism of action compared to anti-TNF agents 
and could conceivably induce distinct changes in the microbiota. 
Participants receiving vedolizumab were excluded in order to re-
move this as a potential confounding factor.
3  | RESULTS
3.1 | Participant characteristics
The “Metabolic and Microbiome Profiling in Paediatric IBD” 
study recruited 53 children. Of these, 25 patients with estab-
lished paediatric CD on maintenance biological therapy were 
eligible for inclusion in this analysis (Figure S1). There were 11 
patients in each of the low and high calprotectin groups. Three 
patients met inclusion criteria, but did not have a calprotectin 
value, these patients were included in analyses which did not re-
quire calprotectin value.
Height was significantly lower in the high calprotectin group (dif-
ference in mean z score −1.22, 95% CI −2.26 to −0.18, P = 0.025). 
There were no significant differences in other baseline character-
istics. Disease location, and treatment with biological and immuno-
modulatory therapy were similar between groups (Table 1).
Clinical disease activity was not significantly different between 
groups. Mean paediatric CD activity index (PCDAI) ± standard devi-
ation was 19 ± 22 in the high calprotectin group vs 13.8 ± 14 in the 
low calprotectin group (P = 0.50). Median calprotectin in the low cal-
protectin group was 38 μg/g (range 23-97) compared to 1338 μg/g 
(range 141-3933) in the high calprotectin group (P = 0.0016).
3.2 | Metataxonomic analysis
Bacterial diversity metrics and community composition were similar 
in the high and low calprotectin groups. There was no significant dif-
ference in Shannon diversity index, Pielou's evenness index or species 
richness between groups (Figure 1A). No samples were identified as 
outliers by these diversity metrics. An NMDS plot of weighted UniFrac 
distance showed no clear separation of the two groups by beta diver-
sity (Figure 1B). This finding was consistent with non-significance on 
PERMANOVA of weighted UniFrac distance (P = 0.33). The sample 
with the highest calprotectin concentration (3933 μg/g) was identified 
as an outlier on weighted UniFrac distance and was not included in the 
NMDS plot or PERMANOVA calculation.
There was a sixfold increase in the relative abundance of the 
Dialister genus in the low calprotectin group compared to the high 
calprotectin group. Dialister species were the seven most abundance 
genus in the low calprotectin group with a mean proportion of se-
quences of 3.4% (SD 2.22), compared to the 30 most abundant in 
the high calprotectin group with a mean proportion of sequences of 
0.53% (SD 0.79) (difference of means −2.88%, 95% CI −4.31 to −1.53, 
q = 0.00999; Figure 2). The relative abundance of Dialister was nega-
tively correlated with calprotectin (Spearman's ρ = −0.73, P = 0.0001). 
There were no other significant differences in relative abundance with 
q < 0.05 and difference in the mean proportion of sequences >1% at 
genus level (Figure S2), or at higher taxonomic levels.
Inferred metagenomic analysis identified no significant differ-
ences in KEGG ortholog, KEGG pathway or BioCyc feature expres-
sion between the two groups.
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3.3 | Protease activity
Protease activity was assayed in all thawed stool samples. Outlier 
analysis detected an anomalously high protease activity of 1809 
relative units in the sample with the highest calprotectin concentra-
tion (3933 μg/g), this result was removed from further analysis of 
protease and protease subtype activity.
There was no significant difference in total protease activity be-
tween the groups. Mean protease activity was 587 relative units (SD 
227) in the high calprotectin group vs 465 relative units (SD 254) in 
the low calprotectin group (difference of means 121, 95% CI −99 to 
342, P = 0.26; Figure 3A).
The activity of protease subtypes was assayed by addition of dif-
ferent combinations of protease inhibitors to control the spectrum 
of inhibition. After Bonferroni correction there was no significant 
difference in the activity of any protease subtypes (Figure 3B-D).
3.4 | 1H-NMR-based metabolic profiling
1H-NMR spectroscopy was performed on faecal water prepared 
from thawed stool samples. Analysable spectra were not obtained 
for three samples from the high calprotectin group and one sample 
without a calprotectin value. The remaining data set was modelled 
using high and low calprotectin groups as a dichotomous classifier 
(n = 19). The MCCV-PLS-DA model discriminated samples from high 
and low calprotectin groups with explained variance (R2Y) of 0.87 
and capability of prediction (Q2Y) of 0.41 (Figure 4A).
The principal metabolic discriminators used by the model were 
pentanoate, which was increased in the low calprotectin group, and 
lysine which was increased in the high calprotectin group (Figure 4). 
Peak assignments of both metabolites were confirmed by multiple 
two-dimensional NMR experiments and STORM method (Table S3 
and Figure S4). Other regions of the 1D spectra detected as signif-
icant by the model did not correspond to assignable metabolites 
(Figure 4B).
The relative concentrations of pentanoate and lysine in the high 
and low calprotectin groups were approximated using the integrals 
of their resonance peaks at 1.30 ppm (δ1H range from 1.27 to 1.33) 
and 1.73 (δ1H range from 1.69 to 1.76) respectively (Figure 4C). 
The mean concentration of pentanoate was 1.35 times greater 
in the low calprotectin group compared to the high calprotectin 
group (95% CI 1.03-1.68 times greater, P = 0.0361) and had strong 
negative correlation with calprotectin (ρ = −0.61, P = 0.006). The 
relative concentration of lysine was 1.54 times greater in the high 
calprotectin group (95% CI 1.05-2.03 times greater, P = 0.028) 
and had strong positive correlation with calprotectin (ρ = 0.58, 
P = 0.009).
3.5 | Multiomic integration
Relative abundance data from metataxonomic analysis were cor-
related with 1D 1H-NMR spectral features using Spearman's rank 
correlation coefficient with Storey-Tibshirani correction for mul-
tiple testing (n = 21). Dialister species abundance had significant 
Low calprotectin High calprotectin
P 
value
Number 11 11
Age, mean ± SD (y) 13.4 ± 3.30 14.4 ± 2.20 0.414
Disease duration, 
mean ± SD (mo)
30.7 ± 13.5 29.8 ± 13.8 0.878
Time on biologics, 
Mean ± SD (mo)
18.6 ± 11.4 19.1 ± 13.8 0.921
Height (z score) 0.534 ± 1.35 −0.689 ± 0.689 0.025
BMI (z score) 0.174 ± 1.17 0.0648 ± 1.24 0.846
Biological therapy Infliximab 91% Infliximab 91%
Vedolizumab 9% Vedolizumab 9% 0.99
Immunomodulator Azathioprine 18% Azathioprine 45% —
Methotrexate 18% Methotrexate 0%
Mercaptopurine 9% Mercaptopurine 0%
Disease location L1 0% L1 9% —
L2 45% L2 36%
L3 45% L3 45%
L4a/b 54% L4a/b 63%
Perianal 9% Perianal 27%
Note: P values calculated using unpaired unequal variance t test (Welch's test) for continuous 
variables, and chi-squared test for categorical variables where validity requirements met.
TA B L E  1   Baseline characteristics of 
the low and high calprotectin groups
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positive correlation (ρ > 0.5, P < 0.05) with the concentration of 
pentanoate and ß-alanine, and significant negative correlation 
(ρ < −0.5, P < 0.05) with phenylalanine (Figure S3 and Table S4). 
The presence of these metabolites was confirmed by multiple two-
dimensional NMR approaches and STORM method (Table S4 and 
Figure S4). Unlike pentanoate, there was no significant difference in 
the relative concentration of beta-alanine or phenylalanine between 
the high and low calprotectin groups (P = 0.25 and P = 0.12 respec-
tively). Four other bacterial genera (Escherichia/Shigella, Unclassified 
Lachnospiraceae, Roseburia and Veillonella) had significant correla-
tions with metabolites, as shown in Table S4.
3.6 | Metabolic potential of Dialister species
Metataxonomic and metabolite data were used to create a con-
densed reaction network in MetaboNetworks (Figure S5).47 This 
illustrates metabolic pathways available in the microbiome of par-
ticipants, and how they lead to biosynthesis or degradation of sig-
nificant metabolites.
The potential contribution of Dialister to the production or 
degradation of significant metabolites was assessed by comparing 
its metabolic network map to the microbiome reaction network. 
Species level analysis of the Dialister genus was performed to iden-
tify the most appropriate reference genome to use to generate its 
metabolic network map. This revealed that 79% of the difference 
in the Dialister genus relative abundance between the groups was 
attributable to D invisus, and that the relative abundance of D invisus 
was significantly higher in the low calprotectin group (P = 0.0069) 
(Table S2). A metabolic network map was created from the genome 
of a representative strain from the D invisus species (D invisus JCM 
17566). This network map acts as a partial approximation of the true 
metabolic potential of Dialister species, it is unable to account for 
variation among the different strains of the species, and does not 
contain all metabolic processes which occur within this strain.
The metabolic network of D invisus JCM 17566 includes the succinate 
pathway, which is a major route for propionate formation. Propionate 
can be coupled to yield pentanoate (Figure S5). The sequenced genome 
of D invisus JCM 17566 does not feature any annotated genes for the 
biosynthesis or degradation of beta-alanine or phenylalanine.
F I G U R E  1   Comparison of microbial 
diversity metrics and community 
composition between high and low 
calprotectin groups. A, Scatter plots with 
mean and 95% confidence interval for 
alpha diversity (Shannon index), species 
richness, and evenness (Pielou's index). 
B, Non-metric multidimensional scaling 
(NMDS) plot of weighted UniFrac distance 
with 95% confidence ellipses. Red dots 
and ellipse = high calprotectin, green 
dots and ellipse = low calprotectin. P 
value calculated using PERMANOVA. 
[Correction added on September 21, 
2020, after first online publication: A typo 
in the word "calprotectin" in the X-axes 
of Figure 1A has been corrected.]
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3.7 | Sensitivity analyses
Two sensitivity analyses were performed. The first excluded participants 
with faecal calprotectin values within the range of suggested thresholds 
for mucosal healing (100-300 μg/g), leaving only those with calprotectin 
values very highly predictive of mucosal healing or inflammation. One pa-
tient from the high calprotectin group with a faecal calprotectin value of 
141 μg/g was excluded. The second sensitivity analysis excluded patients 
receiving maintenance therapy with vedolizumab rather than an anti-
TNF agent. This removed potential bias resulting from different therapy 
induced changes to the microbiota. Two patients were excluded, one 
from each group. The metataxonomic and metabolomic findings of the 
primary analysis were reproduced in both sensitivity analyses (Table S5).
4  | DISCUSSION
This study investigates changes in the microbiota associated with mu-
cosal healing, as indicated by calprotectin level <100 μg/g, in a cohort 
of patients with established paediatric CD receiving maintenance bio-
logical therapy. There were no significant differences in alpha or beta 
diversity between the high and low calprotectin groups.
Interestingly, there was significantly greater relative abundance of 
bacteria from the Dialister genus in patients who had low calprotectin 
levels, and the relative abundance of Dialister had a strong negative 
correlation with calprotectin. The difference in Dialister relative abun-
dance was largely attributable to the D invisus species.
Dialister is obligately anaerobic or microaerophilic members of the 
firmicutes phylum. Among healthy adults they have been noted to have 
a bimodal abundance distribution, being either abundant or nearly ab-
sent, with decreased temporal stability in intermediate states.51 Dialister 
species are known to have reduced abundance in adult and paediat-
ric CD patients relative to healthy controls.52,53 Interestingly Dialister 
also has higher relative abundance in CD patients who are in remission 
following ileocaecal resection than those who have post-operative re-
currence.54 It is possible that Dialister, with its bimodal abundance dis-
tribution, acts as a biomarker of mucosal inflammation. Alternatively, 
Dialister may influence disease activity via its metabolic activity.
An estimate of D invisus's metabolic potential was made by pro-
ducing a metabolic map from its protein coding genes which have 
been linked to metabolic pathways. This is not able to provide a 
complete account of its metabolic activity but did identify potential 
production of propionate. Production of propionate and acetate by 
D invisus has been confirmed in culture experiments.55 Propionate is 
utilised in pentanoate formation. The positive correlation of Dialister 
with pentanoate observed in our study is consistent with Dialister 
promoting the formation of pentanoate, either through increasing 
the availability of its precursor or by a more direct mechanism.
Pentanoate, also known as valerate, was identified as a key indica-
tor of mucosal healing by a machine-learning model utilising spectral 
data from 1H-NMR metabolomic analysis to distinguish high and low 
calprotectin groups. The relative concentration of pentanoate was 
higher in the low calprotectin group and was negatively correlated with 
calprotectin. Pentanoate has previously been found to be deficient in 
stool samples from patients with CD compared to controls,17 and an 
inverse relationship with clinical disease activity has been described in 
adult CD.56,57 In paediatric CD levels of pentanoate have been shown 
to increase with successful exclusive enteral nutrition treatment.58 An 
association with mucosal healing has not previously been described.
In vitro evidence shows that pentanoate has marked immunomodu-
latory effects on lymphocytes through promoting AKT-mTOR signalling 
and enhancing histone acetyltransferase activity, leading to increased 
IL-10 and suppressed IL-17 production.20 Pentanoate treatment de-
creased Th17 cell differentiation and reduced acute inflammation in a 
mouse model of experimental autoimmune encephalitis.20 In addition 
to its immunomodulatory effects pentanoate has also been found to im-
pair vegetative growth of Clostridioides difficile in vitro, and supplemen-
tation has been proposed as a possible treatment strategy in C difficile 
infection.59 The association of pentanoate with mucosal healing demon-
strated in our study is consistent with its described effects on lympho-
cytes and pathogenic microbiota. It supports a model in which reduced 
concentration of pentanoate contributes to the pathogenesis of CD.
Lysine was also identified as a discriminator by the machine learn-
ing model; its relative concentration was higher in the high calprotectin 
group and was positively correlated with calprotectin. Faecal lysine has 
previously been found to be present in higher concentration in CD than 
in healthy controls,60 but it is not known whether it has any biological 
significance. Lysine is known to competitively inhibit uptake of arginine 
at the CAT1 transporter, and thus could reduce uptake of arginine which 
has immunomodulatory properties.61 Alternatively, the increase in lysine 
may be secondary to inflammation induced changes in microbial amino 
acid metabolism, and could be a useful biomarker of disease activity.
F I G U R E  2   Mean relative abundance of Dialister in high and 
low calprotectin groups, bars indicate 95% confidence intervals. q 
value calculated using two-sided White's non-parametric t test with 
Benjamini-Hochberg correction for multiple testing. [Correction 
added on September 21, 2020, after first online publication: A typo in 
the word "calprotectin" in the X-axis of Figure 2 has been corrected.]
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Beta-alanine and phenylalanine were correlated with Dialister, 
however, their relative concentrations were not significantly different 
between the high and low calprotectin groups and the machine learn-
ing model did not identify either metabolite as a discriminator. It is not 
clear that beta-alanine or phenylalanine are associated with mucosal 
healing.
Given the significant metataxonomic and metabolomic differ-
ences between the high and low calprotectin groups it is surprising 
no differences were detected by inferred metagenomic analysis. 
However, apart from Dialister there were no large-scale changes in 
microbial community composition in our study, and the lack of dif-
ference likely reflects the limitations of inferred approaches in de-
tecting smaller metagenomic differences.
No difference in total protease activity or protease subtype 
activity was found between high and low calprotectin groups. 
Protease subtype analysis was limited by non-specificity of protease 
inhibitors, therefore several significant protease classes such as ma-
trix-metalloproteases could not be assessed.
This study has several limitations. It is a cross sectional analysis 
of 25 participants, longitudinal analysis of a larger data set would 
give further insights on how the microbiota and metabolome change 
with disease activity and would aid detection of smaller changes. 
Use of metagenomic sequencing would enhance understanding of 
how changes in the microbiota influence the metabolome, and tar-
geted metabolomic approaches would allow quantification and im-
proved detection of metabolites.
Use of a faecal calprotectin level under 100 μg/g as a biomarker 
for mucosal healing is a potential limitation of this study, as there is 
uncertainty regarding the appropriate threshold to indicate muco-
sal healing, with values in the range of 100-300 μg/g supported. A 
sensitivity analysis which excluded patients with “borderline” faecal 
calprotectin values was performed to address this and confirmed all 
F I G U R E  3   Scatter plots of protease 
activity (expressed as equivalent 
concentration of trypsin in μg/ml) in 
patients with high and low calprotectin. 
Bars indicate mean and 95% confidence 
interval. Unpaired t test was performed 
for all samples, Bonferroni correction was 
applied for protease subtype activity. A, 
Total protease activity (uninhibited). B-D, 
Protease subtype activity, expressed as 
reduction in protease activity caused 
by addition of inhibitors (Δ protease 
activity); antipain-dihydrochloride (B); 
leupeptin (C); antipain-dihydrochloride, 
pepstatin, aprotinin (D). [Correction 
added on September 21, 2020, after first 
online publication: A typo in the word 
"calprotectin" in the X-axes of Figure 3 
has been corrected.]
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findings from the primary analysis. There is additional concern the 
accuracy of faecal calprotectin may be lower in ileal disease,9 but in 
this cohort only one patient had isolated ileal disease and they had a 
very raised calprotectin level over 2000 μg/g.
In this study clinical disease activity did not correlate closely with 
calprotectin. This observation is consistent with many other studies 
in adult and paediatric CD and highlights the need to consider both 
clinical remission and mucosal healing as distinct therapeutic targets.62
This study addresses an important and clinically relevant ques-
tion—are there microbial or metabolic features in established paedi-
atric CD which could contribute to sustained mucosal inflammation 
or promote mucosal healing? It reports a comprehensive multiomic 
analysis of a well-phenotyped cohort, which is representative of 
many patients with established paediatric CD. It has several im-
portant findings. Lysine is increased in patients with ongoing mu-
cosal inflammation, this association warrants further investigation 
to identify potentially relevant disease mechanisms and biomarkers. 
Most significantly, D invisus is more abundant in patients with muco-
sal healing and has the potential to facilitate pentanoate formation. 
Pentanoate, which has known immunomodulatory properties highly 
relevant to CD, is also increased in those with mucosal healing and 
is correlated with Dialister relative abundance. The Dialister penta-
noate relationship could therefore represent a novel and targetable 
therapeutic axis which promotes mucosal healing in CD.
F I G U R E  4   A, MCCV-PLS-DA score plot derived from 1D 1H-NMR spectra of faecal water samples, indicating the differentiation between 
high calprotectin group (red) and low calprotectin group (green). The model is comprised of Kernel Density Estimate (KDE) of the predicted 
scores (Tpred) for both groups. Dots represent the metabolic profile of each patient from the study cohort when its corresponding NMR 
spectrum and calprotectin values were available (n = 19). The fit and predictability of the model were obtained and expressed as R2Y 
(explained variance) and Q2Y (capability of prediction) values. B, MCCV-PLS-DA loading plot. Top depicts the average 1D 1H-NMR spectrum 
of the 19 faecal water samples. The bottom depicts the Manhattan plot showing − log10(q) × sign of regression coefficient (β) of the MCCV-
PLS-DA model that in conjunction represent the contribution of each variable on it. In green, metabolites are shown that are significantly 
higher in the low calprotectin group, and in red metabolites significantly higher in the high calprotectin group. Labels: 1.1-1.3 = lysine 
(1.73(m), 1.46(m), 3.04 (t)), 2 = pentanoate/valerate (1.30(m)). C, Fragments from the average 1D 1H-NMR spectra from the high calprotectin 
(red, n = 8) and low calprotectin (green, n = 11) groups, showing the less overlapped resonances detected as significant in the MCCV-PLS-
DA model corresponding to lysine (1.2, 1.73(m), 1.3, 1.46(m)) and pentanoate/valerate (2, 1.30(m)). MCCV, Monte Carlo Cross-Validation; 
PLS-DA, partial least squares discriminant analysis
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